171P: Carboplatin–paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC

Authors :: M.A. van der Drift
A. Timmer-Bonte
H. Van Groningen
C. Smits-Van der Graaf
M. Dohmen
D.G.M. van den Hurk
Source :: Journal of Thoracic Oncology. 11(4)
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: 0301 basic medicine
Oncology
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Bevacizumab
business.industry
Carboplatin/paclitaxel
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
In patient
Erlotinib
business
medicine.drug

Full Text Access

Tools